OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ovid Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.17+0.02 (+0.93%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ovid Therapeutics Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Royalty, License and Termination Agreement | $230.70M | $223.50M | – | – | – | – | 3181.2% | +3.2% |
| License and other revenue | – | – | – | $1.50M | $12.38M | $12.62M | – | – |
| Related Party | – | – | – | $0 | $196.00M | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Ovid Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.